Roche Finland bjuder in till ett webinair om Hemofili A
Behandling med Emicizumab ▼ vid Hemofili A för personer utan inhibitorer.†‡
Inbjudna föreläsare: Prof Guy Young och Prof Victor Jimenez-Yuste
Onsdagen den 19 maj 2021 från kl. 15.30 till 18.00
Mötet riktar sig till Hälso- och sjukvårdspersonal som handlägger och behandlar patienter med Hemofili A och har som syfte att diskutera klinisk erfarenhet i Europa av behandling med HEMLIBRA till personer med hemofili A.
Det är möjligt att delta i evenemanget på egen hand från datorn.
Program
Onsdag 19 maj | |
15.30 | Välkommen Anssi Linnankivi, Medical Director, Roche |
15.35 | Introduktion Chair Prof. Riitta Lassila, Helsinki University Hospital |
15.45 | How I treat adults with Hemophilia A with emicizumab Assoc. Prof. Víctor Jiménez-Yuste, Hospital Universitario La Paz |
16.20 | How I treat children with Hemophilia A with emicizumab Prof. Guy Young, Children’s Hospital Los Angeles/University of Southern California Keck School of Medicine |
16.55 | Bensträckare |
17.00 | Emicizumab & lab monitoring Dr. Tímea Szántó, Helsinki University Hospital |
17.20 | Paneldiskussion |
17.55 | Avslutande ord Anssi Linnankivi, Roche |
Föreläsare
Riitta Lassila, MD, PhD
Director of Coagulation Disorders Unit, European Haemophilia and Allied Disorders (EAHAD) Comprehensive Care Centre, Department of Haematology and Comprehensive Cancer Centre
Professor of Coagulation Medicine in the University of Helsinki and Helsinki University Hospital. She is engaged with clinical and translational studies, including outcome markers and new treatment modalities of Coagulation disorders.
Prof. Lassila the Chair of the Finnish Blood diseases research foundation and the former secretary of the executive board of EAHAD. Prof. Lassila has authored over 300 articles in scientific peer-review journals.
Víctor Jiménez-Yuste
La Paz University Hospital, Madrid, Spain
Víctor Jiménez-Yuste is an Associate Professor in the Haematology Department at the Autónoma University of Madrid, Spain (2004), and Head of the Hematology Department at La Paz University Hospital, Madrid, Spain (2013). After his medical degree at Valladolid University (1990), Spain, Professor Jiménez-Yuste specialised in haematology at La Paz University Hospital (1996), Madrid, Spain. He was awarded his PhD by the Autónoma University of Madrid where he completed his thesis studying haemophilia and HIV infection (1998).
Professor Jiménez-Yuste is a Vicepresident of the Spanish Society of Hematology. His research interests include the management of inherited bleeding disorders, immune thrombocytopenia (ITP) and acquired haemophilia, and he has published more than 200 papers in various journals covering these issues.
Guy Young, MD
Children’s Hospital Los Angeles Professor of Pediatrics University of Southern California Keck School of Medicine
Guy Young, MD, received his medical degree from the State University of New York at Stony Brook School of Medicine in Stony Brook, New York. He completed a residency in pediatrics at Schneider Children’s Hospital at Long Island Jewish Medical Center, Albert Einstein College of Medicine in New York, and a fellowship in pediatric hematology/oncology at Children’s National Medical Center, George Washington University School of Medicine in Washington, D.C.
Dr. Young is the Director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles and a Professor of Pediatrics at the University of Southern California’s Keck School of Medicine.
His current research activities encompass clinical trials in hemophilia, the use of novel anticoagulants in children, and the development of the global hemostasis assays to monitor the effects of medications used to treat bleeding in hemophilia.
Dr. Young has published many journal articles, abstracts, and textbook chapters and has delivered lectures, workshops, and presentations at national and international meetings. He is the past chair of the Scientific and Standardization Committee
on Factor VIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasis and
also served on the Scientific Subcommittee on Hemostasis for the American Society of Hematology. He has been awarded the National Hemophilia Foundation Physician of the Year Award in 2013.
Tímea Szántó, MD, PhD
Clinician at the Coagulation Disorders Unit, Helsinki University Central Hospital, Helsinki, Finland
She holds a speciality training in Clinical Chemistry and now she is completing her residency training in Internal Medicine
at Helsinki University Central Hospital. She holds a Ph.D. undertaken under a joint university program involving Katholieke Universiteit Leuven, Belgium, and University of Debrecen, Hungary.
She is engaged in different research projects within the research area of coagulation disorders, with main focus on the complex clinical and laboratory evaluation of patients with inherited bleeding disorders, such as Von Willebrand disease, haemophilia and hypo/dysfibrinogenemia. Member of the Nordic Haemophilia Council (NHC).
Elina Lehtinen, MD, PhD, Consultant
Coagulation Disorders Unit (EHCCC), Division of Haematology Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland
Dr. Lehtinen graduated with MD, PhD from Helsinki University, Finland in 1993. Her doctoral thesis was in basic science research involving novel leukaemia cell receptor tyrosine kinases (advisor Prof. Kari Alitalo). She then continued her postgraduate training in the United States, first in internal medicine and then in haematology (University of Pennsylvania, Philadelphia, PA) focusing in benign haematology and coagulation disorders. She received her ABIM Certification in Haematology in 1998. She did her post-doctoral research project: Characterization of immune responses in haemophilia B gene-therapy using a mouse model at Prof. Katherine A. High’s lab in Philadelphia. She has gained experience in translational research and clinical experience in inherited bleeding and thrombotic disorders at the Penn Comprehensive Haemophilia and Thrombosis Center, Philadelphia, Pennsylvania, directed by Dr. Barbara Konkle. Since 2005 she has worked as a consultant and adjunct professor at the Coagulation Disorders Unit of the Helsinki University Central Hospital directed by Prof. Riitta Lassila. Her research and clinical interests include comprehensive care in haemophilia, novel therapies and gene therapy. She has published more than 30 original articles, reviews and book chapters in the area. She is a board-member of the Finnish Haemophilia patient organization and past director of the Finnish Haemophilia Group.National Hemophilia Foundation Physician of the Year Award in 2013.
▼ Detta läkemedel är föremål för utökad övervakning. Detta kommer att göra det möjligt att snabbt identifiera ny säkerhetsinformation. Hälso- och sjukvårdspersonal uppmanas att rapportera varje misstänkt biverkning. Rapporteringen ska göras till Läkemedelsverket www.lakemedelsverket.se eller direkt till Roche AB via sverige.safety@roche.com eller via telefon 08 - 726 12 00.
Hemlibra® (emicizumab), Monoklonal antikropp, B02BX06. (Rx, F) .
Hemlibra är subventionerat till patienter vars inhibitorutveckling inte hävts genom upprepade ITI-behandlingar.
Indikation: Hemlibra är indicerat som förebyggande behandling av blödningsepisoder hos patienter med: Hemofili A (medfödd faktor VIII brist) med inhiberande antikroppar mot faktor VIII, samt svår hemofili A (medfödd faktor VIII brist, FVIII < 1%) utan inhiberande antikroppar mot faktor VIII. Hemlibra kan användas hos alla åldersgrupper.
Kontraindikationer: Överkänslighet mot emicizumab eller mot något hjälpämne i läkemedlet.
Varningar och försiktighet: Hemlibra ökar koagulationsförmåga. Den dos av bypassläkemedel som krävs kan därför vara lägre än den som används utan Hemlibra. Patienter som får Hemlibraprofylax ska kontrolleras avseende utveckling av trombotisk mikroangiopati och tromboembolism när aktiverat protrombinkomplex (aPCC) administreras. Användning av aPCC ska undvikas om andra behandlingsmöjligheter/-alternativ finns tillgängliga. Hemlibra påverkar laboratorie analyser av aktiverad partiell tromboplastintid (aPTT) och alla analyser baserade på aPTT såsom enskilda faktoranalyser av VIII-aktivitet. På grund av Hemlibras långa halveringstid bör ovan rekommendationer följas under minst 6 månader efter utsättande.
Dosering: Den rekommenderade dosen är 3 mg/kg kroppsvikt en gång per vecka under de första 4 veckorna (laddningsdos), följt av underhållsdosering med antingen 1,5 mg/kg en gång per vecka,3 mg/kg varannan vecka, eller 6 mg/kg var fjärde vecka, alla doser administreras som en subkutan injektion.
Förpackningar: Injektionsvätska, lösning 30 mg (30 mg/ml). Injektionsvätska, lösning 60 mg, 105 mg, 150 mg (150 mg/ml).
Senaste produkt resume uppdaterad 2020-12-07
För priser och fullständig information se www.fass.se, Roche AB, Tel 08-726 1200.
†Detta webinar är kostandsfritt och arrangeras av Roch Finland.
‡Observera att sessionen kommer att modereras i överensstämmelse med gällande regler.
Dina personuppgifter. Roche AB lagrar och använder de personuppgifter som insamlas från dig för administrering av ditt ärende. Om du väljer att lämna din e-postadress samtycker du till att e-post används för kommunikation med dig i detta ärende. Läs mer här i vår integritetspolicy.
Kontakta Renée Dittlau - renee.dittlau@roche.com vid frågor.
M-SE-00000578 Maj 2021